Cargando…
The dynamics of biomarkers across the clinical spectrum of Alzheimer’s disease
BACKGROUND: Quantifying changes in the levels of biological and cognitive markers prior to the clinical presentation of Alzheimer’s disease (AD) will provide a template for understanding the underlying aetiology of the clinical syndrome and, concomitantly, for improving early diagnosis, clinical tri...
Autores principales: | Hadjichrysanthou, Christoforos, Evans, Stephanie, Bajaj, Sumali, Siakallis, Loizos C., McRae-McKee, Kevin, de Wolf, Frank, Anderson, Roy M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293779/ https://www.ncbi.nlm.nih.gov/pubmed/32534594 http://dx.doi.org/10.1186/s13195-020-00636-z |
Ejemplares similares
-
Association of TDP-43 proteinopathy, cerebral amyloid angiopathy, and Lewy bodies with cognitive impairment in individuals with or without Alzheimer’s disease neuropathology
por: Thomas, David X., et al.
Publicado: (2020) -
The importance of endpoint selection: How effective does a drug need to be for success in a clinical trial of a possible Alzheimer’s disease treatment?
por: Evans, Stephanie, et al.
Publicado: (2018) -
Potential Factors Associated with Cognitive Improvement of Individuals Diagnosed with Mild Cognitive Impairment or Dementia in Longitudinal Studies
por: Hadjichrysanthou, Christoforos, et al.
Publicado: (2018) -
Alzheimer's disease progression and risk factors: A standardized comparison between six large data sets
por: Evans, Stephanie, et al.
Publicado: (2019) -
Combining hippocampal volume metrics to better understand Alzheimer’s disease progression in at-risk individuals
por: McRae-McKee, K., et al.
Publicado: (2019)